CU24157B1 - Composición farmacéutica de liberación prolongada de trimetazidina - Google Patents

Composición farmacéutica de liberación prolongada de trimetazidina

Info

Publication number
CU24157B1
CU24157B1 CU20130016A CU20130016A CU24157B1 CU 24157 B1 CU24157 B1 CU 24157B1 CU 20130016 A CU20130016 A CU 20130016A CU 20130016 A CU20130016 A CU 20130016A CU 24157 B1 CU24157 B1 CU 24157B1
Authority
CU
Cuba
Prior art keywords
trimetazidine
prolonged
release
pharmaceutical composition
pharmaceutical
Prior art date
Application number
CU20130016A
Other languages
English (en)
Other versions
CU20130016A7 (es
Inventor
Patrick Genty
Christophe Hermelin
Jean-Manuel Pean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24157(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CU20130016A7 publication Critical patent/CU20130016A7/es
Publication of CU24157B1 publication Critical patent/CU24157B1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CU20130016A 2012-02-03 2013-01-28 Composición farmacéutica de liberación prolongada de trimetazidina CU24157B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (2)

Publication Number Publication Date
CU20130016A7 CU20130016A7 (es) 2014-10-02
CU24157B1 true CU24157B1 (es) 2016-03-31

Family

ID=47504206

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130016A CU24157B1 (es) 2012-02-03 2013-01-28 Composición farmacéutica de liberación prolongada de trimetazidina

Country Status (48)

Country Link
US (1) US10117838B2 (es)
EP (1) EP2623096B1 (es)
JP (1) JP6338818B2 (es)
KR (2) KR20130090365A (es)
CN (2) CN103239425A (es)
AP (1) AP2013006693A0 (es)
AR (1) AR089861A1 (es)
AU (1) AU2013200481B2 (es)
BR (1) BR102013002524B1 (es)
CA (1) CA2805471C (es)
CL (1) CL2013000336A1 (es)
CO (1) CO6720159A1 (es)
CR (1) CR20130037A (es)
CU (1) CU24157B1 (es)
CY (1) CY1121696T1 (es)
DK (1) DK2623096T3 (es)
DO (1) DOP2013000024A (es)
EA (1) EA030227B1 (es)
EC (1) ECSP13012415A (es)
ES (1) ES2735053T3 (es)
FR (1) FR2986431B1 (es)
GE (1) GEP20156342B (es)
GT (1) GT201300032A (es)
HR (2) HRP20130082A2 (es)
HU (1) HUE043942T2 (es)
IL (1) IL224495B (es)
JO (1) JO3505B1 (es)
LT (1) LT2623096T (es)
MD (1) MD4622C1 (es)
MX (1) MX363302B (es)
MY (1) MY162599A (es)
NI (1) NI201300014A (es)
PE (1) PE20131119A1 (es)
PH (1) PH12013000031A1 (es)
PL (1) PL2623096T3 (es)
PT (1) PT2623096T (es)
PY (1) PY1303869A (es)
RO (1) RO128004A3 (es)
RS (2) RS20130034A1 (es)
RU (1) RU2621128C2 (es)
SG (1) SG192386A1 (es)
SI (1) SI2623096T1 (es)
SV (1) SV2013004396A (es)
TR (1) TR201906390T4 (es)
TW (1) TWI508755B (es)
UA (1) UA118742C2 (es)
UY (1) UY34595A (es)
WO (1) WO2013114053A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383944B2 (en) * 2014-04-08 2019-08-20 Dow Global Technologies Llc Dispersion comprising an esterified cellulose ether
EP4378457A3 (en) * 2016-11-21 2024-07-31 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법
WO2025068837A2 (en) * 2023-09-26 2025-04-03 Zim Laboratories Limited A novel extended release pharmaceutical composition of trimetazidine or salt thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (es) * 1960-10-20
FR2490963B1 (fr) 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
DE60042972D1 (de) * 2000-10-05 2009-10-29 Usv Ltd Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
EP1448173A2 (en) * 2001-11-21 2004-08-25 Themis Laboratories Private Limited A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
PL2457563T3 (pl) * 2006-05-09 2017-09-29 Mallinckrodt Llc Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
CN100571703C (zh) * 2006-12-20 2009-12-23 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
KR101122447B1 (ko) * 2007-11-09 2012-03-20 미쓰비시 타나베 파마 코퍼레이션 신규 제제
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
WO2010084397A2 (en) * 2009-01-20 2010-07-29 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
HUE027498T2 (en) * 2009-01-30 2016-10-28 Lupin Ltd Pharmaceutical preparations containing trimetazidine
CA2755814A1 (en) * 2009-03-18 2010-09-23 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
US20110274751A1 (en) * 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Also Published As

Publication number Publication date
RS20130034A1 (sr) 2013-10-31
EP2623096A3 (fr) 2013-10-23
EP2623096A2 (fr) 2013-08-07
TW201332591A (zh) 2013-08-16
NI201300014A (es) 2013-05-13
GT201300032A (es) 2014-06-09
GEP20156342B (en) 2015-08-10
CL2013000336A1 (es) 2014-07-18
PY1303869A (es) 2015-11-02
JP6338818B2 (ja) 2018-06-06
HRP20191072T1 (hr) 2019-11-01
FR2986431A1 (fr) 2013-08-09
WO2013114053A3 (fr) 2013-12-19
CO6720159A1 (es) 2013-07-31
LT2623096T (lt) 2019-05-10
MD4622B1 (ro) 2019-03-31
HUE043942T2 (hu) 2019-09-30
MD20130005A2 (ro) 2013-07-31
JP2013159609A (ja) 2013-08-19
WO2013114053A2 (fr) 2013-08-08
CN106924221A (zh) 2017-07-07
SI2623096T1 (sl) 2019-06-28
MY162599A (en) 2017-06-30
RO128004A3 (ro) 2013-08-30
KR20130090365A (ko) 2013-08-13
UY34595A (es) 2013-09-02
EP2623096B1 (fr) 2019-04-03
FR2986431B1 (fr) 2017-03-17
AU2013200481A1 (en) 2013-08-22
PL2623096T3 (pl) 2019-08-30
RU2013104252A (ru) 2014-08-10
JO3505B1 (ar) 2020-07-05
AP2013006693A0 (en) 2013-01-31
RS58752B1 (sr) 2019-06-28
EA201300079A2 (ru) 2013-07-30
NZ606550A (en) 2014-09-26
KR101918211B1 (ko) 2018-11-14
US20130202710A1 (en) 2013-08-08
IL224495B (en) 2020-08-31
EA201300079A3 (ru) 2013-11-29
PT2623096T (pt) 2019-05-30
CA2805471C (fr) 2018-05-01
CU20130016A7 (es) 2014-10-02
CR20130037A (es) 2013-09-18
MX363302B (es) 2019-03-20
ECSP13012415A (es) 2014-09-30
DOP2013000024A (es) 2014-07-15
RU2621128C2 (ru) 2017-05-31
CN103239425A (zh) 2013-08-14
CA2805471A1 (fr) 2013-08-03
KR20150102922A (ko) 2015-09-09
MD4622C1 (ro) 2019-10-31
MX2013001118A (es) 2013-08-27
PH12013000031B1 (en) 2014-09-22
DK2623096T3 (da) 2019-07-15
CY1121696T1 (el) 2020-07-31
RO128004A0 (ro) 2012-12-28
US10117838B2 (en) 2018-11-06
EA030227B1 (ru) 2018-07-31
SV2013004396A (es) 2013-06-05
TWI508755B (zh) 2015-11-21
PE20131119A1 (es) 2013-10-12
AR089861A1 (es) 2014-09-24
HRP20130082A2 (hr) 2013-08-31
SG192386A1 (en) 2013-08-30
AU2013200481B2 (en) 2015-01-22
TR201906390T4 (tr) 2019-05-21
ES2735053T3 (es) 2019-12-13
UA118742C2 (uk) 2019-03-11
BR102013002524A2 (pt) 2014-09-09
BR102013002524B1 (pt) 2020-02-04
PH12013000031A1 (en) 2014-09-22

Similar Documents

Publication Publication Date Title
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
PT3030262T (pt) Composição farmacêutica de associação
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
PT3725778T (pt) Formulações de enzalutamida
DK2897594T3 (da) Farmaceutisk sammensætning
EP2857482A4 (en) Perfume composition
DK2815752T3 (da) Oral farmaceutisk sammensætning
IL237139A0 (en) Pharmaceutical compositions of memantine
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
IL266415A (en) Innovative pharmaceutical composition
EP2815753A4 (en) ORAL PHARMACEUTICAL COMPOSITION
BR112015008572A2 (pt) formulações de liberação modificada para oprozomib
EP2872339A4 (en) SCOREBOARD
CU24157B1 (es) Composición farmacéutica de liberación prolongada de trimetazidina
EP2905011A4 (en) PERFUME COMPOSITION
BR112015002646A2 (pt) composto e composição farmacêutica
SMT201600419B (it) Composizione farmaceutica contenente fosfolipidi
PL2892528T3 (pl) Kompozycje farmaceutyczne zawierające flurbiprofen
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
PL2908836T3 (pl) Formulacja farmaceutyczna zawierająca kurkuminę
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
BR112014021433A2 (pt) formulações farmacêuticas
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2863894A4 (en) fenofibrate

Legal Events

Date Code Title Description
FG Grant of patent